4
Changes in Ownership
PTC THERAPEUTICS, INC. Filed Acc 0001415889-23-006694
EXEC. VP AND CLO sold 61,923 shares at an average $51.42 ($3,183,830)
- EXEC. VP AND CLO acquired 61,923 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Option exercise 10b5-1 | +3,292 | $30.86 | $101,591 | 78,670 | D: show line 1 in the form |
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Sale 10b5-1 | −3,292 | $51.42 | $169,276 | 75,378 | D: show line 2 in the form |
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Option exercise 10b5-1 | +58,631 | $30.86 | $1,809,353 | 134,009 | D: show line 3 in the form |
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Sale 10b5-1 | −58,631 | $51.42 | $3,014,554 | 75,378 | D: show line 4 in the form |
| Open-market sales · 61,923 sh · avg $51.42 · $3,183,830 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,292 | $30.86 | $101,591 | 58,631 | D: show line 5 in the form |
| Boulding Mark Elliott EXEC. VP AND CLO | 2023-04-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −58,631 | $30.86 | $1,809,353 | 0 | D: show line 6 in the form |
Loading xslF345X04/form4-04192023_080455.xml…